When was Novast Laboratories founded?

Novast Laboratories was founded in 2005 and raised its 1st funding round 4 years after it was founded.

Where is Novast Laboratories located?

Novast Laboratories is headquartered in Nantong, China.

How many employees does Novast Laboratories have?

As of Aug 31, 2026, the latest employee count at Novast Laboratories is 52.

Is Novast Laboratories a funded company?

Novast Laboratories is a funded company, having raised a total of $186M across 3 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Jul 02, 2009.

When was the latest funding round of Novast Laboratories?

Novast Laboratories' latest funding was a $***** Series E round on May 09, 2020, with participation from 4 investors. Its primary sector is Biopharma Outsourcing. In China, the Biopharma Outsourcing sector has seen $50.6M in funding in 2026 to date.

Where does Novast Laboratories rank among its competitors?

Novast Laboratories ranks 37th amongst 386 active competitors, of which 15 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Almac Group, which secured $417K in Sep, 2022.

Who are the top competitors of Novast Laboratories?

Novast Laboratories' top competitors include Concord Biotech, Biophore and Almac Group. Among them, Almac Group secured the most recent funding round in September, 2022.

Novast Laboratories - 2026 Company Profile, Funding & Competitors

Novast Laboratories is a series E company based in Nantong (China), founded in 2005. It operates as a Researches and develops finished products and API formulations. Novast Laboratories has raised $186M in funding from investors like Legend Capital, Xiamen C&D Metals and SAIF Partners. The company has 386 active competitors, including 15 funded and 91 that have exited. Its top competitors include companies like Concord Biotech, Biophore and Almac Group.

Company Details

Novast Laboratories, a subsidiary of Novast Holdings focuses on the design and development of finished products and API formulations for the worldwide markets and offers contract development and manufacturing services for both generic and innovator companies. It is an US FDA-inspected generic and speciality pharmaceutical company with business units based in the United States and China. It has signed a development and supply agreement with Eli Lilly and company in 2012 to jointly develop and commercialize several branded products in the China market.Their product portfolio includes oral contraceptives, hormonal drug products and other conventional dosage forms, including high containment oncology dosage forms (HPAPIs).

Key Metrics

Founded Year

2005

Location

Nantong, China

Stage

Series E

Total Funding

$186M in 3 rounds

Latest Funding Round

Series E, May 09, 2020, $*****

Investors

Legend Capital & 12 more

Ranked

37^th among 386 active competitors

Employee Count

52 as on Aug 31, 2026

Similar Companies

Concord Biotech & 432 more

View Novast Laboratories' full profile

Novast Laboratories has raised a total funding of $186M over 3 rounds. Its first funding round was on Jul 02, 2009. Its latest funding round was a Series E round on May 09, 2020 for $*****. 4 investors participated in its latest round. Novast Laboratories has 13 institutional investors.

Here is the list of recent funding rounds of Novast Laboratories:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 09, 2020	1184247	Series E	8842008	6341588	3721764	4226460
Jun 12, 2012	4863456	Series C	9879460	3490286	8787129	Lilly
Jul 02, 2009	9099498	Series C	5859672	9173975	SAIF Partners	New Enterprise Associates & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Novast Laboratories's funding rounds and investors

Novast Laboratories' employee count trend

Novast Laboratories has 52 employees as of Aug 26. Here is Novast Laboratories's employee count trend over the years:

Employee count trend for Novast Laboratories

Uncover Novast Laboratories' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Novast Laboratories include Concord Biotech, Biophore and Almac Group. Here is the list of Top 10 competitors of Novast Laboratories, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Concord Biotech 1984, Ahmedabad (India), Public	CDMO focused on manufacturing API	$11.3M	Quadria Capital, Helix Investments & 18 others	69/100
2nd	Biophore 2007, Hyderabad (India), Seed	Development and manufacturing of niche pharmaceutical products for the generic industry	$2.74M	Ontario & 6 others	62/100
3rd	Almac Group 2001, Craigavon (United Kingdom), Series D	CRAMS company offering preclinical development and CDMO services, also offering companion diagnostic development	$339M	Genomic Health, Gates & 4 others	57/100
4th	Indoco Remedies 1947, Mumbai (India), Public	Provider of APIs manufacturing and formulation services	-	Baring Private Equity Partners	54/100
5th	Jagsonpal 1964, Delhi (India), Public	Traditional company manufacturing bulk drugs and finished formulations	-	Convergent, Aresko	53/100
6th	Wanbury Limited 1990, Mumbai (India), Public	Manufacturer of anti-diabetic drugs	-	-	53/100
7th	Galenicum 2003, Barcelona (Spain), Late Stage	Turnkey solutions for drug development, manufacturing and regulatory approvals	-	Peninsula Capital	52/100
8th	Amino 1958, Frellstedt (Germany), Unfunded	CDMO focused on amino acids and small molecules	-	-	51/100
9th	Aizant 2005, Hyderabad (India), Series A	Company offering contract development services for small molecules	$7.59M	Zephyr Management, Zephyr Peacock & 39 others	50/100
10th	Asymchem 1995, Morrisville (United States), Public	CDMO providing comprehensive pharmaceutical development and manufacturing solutions globally	-	Hillhouse, CoStone Capital & 5 others	50/100
37th	Novast Laboratories 2005, Nantong (China), Series E	Researches and develops finished products and API formulations	$186M	Goldman Sachs, Lilly & 11 others	44/100